Tautachrome Moves Up To OTCQB; Important Milestone Achieved
Dec 12, 2016 12:00 pm UTC| Business
ORO VALLEY, Ariz., Dec. 12, 2016 -- Tautachrome, Inc. today said it is pleased to announce that it has upgraded from the OTC: Pink to the higher tier OTCQB. The Company's stock will begin trading on the OTCQB today, a...
Akoustis™ Adds New OEM Customer, Purchase Order For High Frequency BAW RF Filters
Dec 12, 2016 12:00 pm UTC| Business
Charlotte, N.C., Dec. 12, 2016 -- Akoustis Technologies, Inc. (OTCQB: AKTS) (“Akoustis” or the “Company”), a manufacturer of patented single-crystal BulkONE™ bulk acoustic wave (BAW) high-band RF filters for mobile and...
Akorn Announces Completion of FDA Re-inspection of Decatur Facility
Dec 12, 2016 12:00 pm UTC| Business
LAKE FOREST, Ill., Dec. 12, 2016 -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) conducted a re-inspection of its Decatur,...
Calithera Biosciences Announces Key Management Changes
Dec 12, 2016 12:00 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, announced that William D. Waddill...
Flexion Therapeutics Submits New Drug Application for Zilretta™ to Treat Knee Osteoarthritis Pain
Dec 12, 2016 12:00 pm UTC| Business
BURLINGTON, Mass., Dec. 12, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead investigational...
Dec 12, 2016 12:00 pm UTC| Business
IRVING, Texas, Dec. 12, 2016 -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata”), a clinical-stage biopharmaceutical company, today announced that, due to adverse market conditions, it has requested withdrawal of its...
Immunomedics Announces Novel Immuno-Oncology Program Targeting Trop-2-Expressing Cancers
Dec 12, 2016 12:00 pm UTC| Business
-- Preclinical Studies Presented at 2016 San Antonio Breast Cancer Symposium (SABCS) ---- Updated Phase 2 Results with Sacituzumab Govitecan (IMMU-132) in Metastatic Triple-Negative Breast Cancer also Reported ---- Full...